Synopsys (SNPS) Valuation Update: How New AI Tools and University Program Shape Investor Outlook

If you are following Synopsys (SNPS) lately, you’ve probably noticed the wave of headlines about its partnership with GlobalFoundries and the bold expansion of Synopsys.ai Copilot’s generative AI tools. These aren’t just routine updates. Together, they signal Synopsys is doubling down on both cutting-edge product development and academic collaboration at the very heart of the semiconductor world. Whether you’re a long-term holder or thinking about initiating a position, the twin moves are bound to influence how you weigh the company’s growth prospects and its value in a fast-evolving industry.

All this comes on the heels of Synopsys’s strong run over the past year, with shares returning 31% and picking up momentum in the past three months. Recent launches like new AI design features, as well as its university pipeline program, suggest Synopsys is working to future-proof its platform and widen its reach, from startups on the cloud to classrooms worldwide. Investors have seen this translate into consistently expanding profit growth and a surge of interest around its ecosystem.

The real question is, after this year’s surge and ongoing innovation, are investors looking at genuine value, or has the market already factored in everything Synopsys could deliver next?

Most Popular Narrative: 6% Undervalued

According to the most widely followed narrative, Synopsys is currently considered moderately undervalued relative to future earnings and revenue expectations.

Synopsys' leadership in AI-driven Electronic Design Automation (EDA) tools and innovation in generative and agentic AI capabilities may lead to significant productivity gains for customers, potentially improving Synopsys' revenue growth and market share in the EDA industry. The robust design activity at advanced nodes, particularly with Fusion Compiler being the platform of choice for 2-nanometer projects, indicates strong future demand and is likely to positively impact revenue growth.

Want to know what is fueling Synopsys’ high valuation? This narrative is built on a bold roadmap of future tech dominance, high profit expectations, and the kind of growth acceleration that typically sends peers scrambling. Curious which precise assumptions support the current price, and how much higher analysts believe it could go? Dive deeper to uncover the crucial figures and analyst logic driving this valuation.

Result: Fair Value of $648.19 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, factors such as regulatory hurdles facing the Ansys acquisition and ongoing economic headwinds in China could present challenges to Synopsys’ future growth expectations.

Find out about the key risks to this Synopsys narrative.

Another View: Market Multiples Paint a Different Picture

While the first approach sees Synopsys as moderately undervalued, comparing its current valuation ratio to the rest of the US Software industry tells another story. This method suggests shares might actually be trading on the expensive side. Could the premium really be justified by future growth, or are expectations getting ahead of reality?

See what the numbers say about this price — find out in our valuation breakdown.

Stay updated when valuation signals shift by adding Synopsys to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Synopsys Narrative

If you think there’s more to the story or you want to dig into the numbers yourself, you can quickly build your own Synopsys thesis from scratch. Do it your way.

A great starting point for your Synopsys research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you want to sharpen your edge, don’t miss the chance to put the Simply Wall Street Screener to work. Get ahead of the crowd and seek out unique opportunities other investors might be missing. Your next big idea could be just a click away.

• Unlock the potential for higher yields when you scan the market for reliable dividend stocks with yields > 3% that consistently pay over 3%.
• Capitalize on the future of medicine by targeting companies driving breakthroughs in patient care with their healthcare AI stocks advancements.
• Catch market inefficiencies before others by zeroing in on undervalued gems fueled by strong fundamentals in our undervalued stocks based on cash flows lineup.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com